FDMT vs MKTX · rev $37.0K vs P/E 13, rev $817.1M
4D Molecular Therapeutics Inc (FDMT) versus MarketAxess Holdings Inc (MKTX) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
MarketAxess Holdings Inc (MKTX) is a capital markets company listed on US.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported MKTX revenue for 2024-12-31 was $817.1M. Net income was $274.2M. Revenue was up 8.6% from 2023-12-31 to 2024-12-31. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
FDMT currently screens at market cap $518.1M. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
Not investment advice. Open the FDMT and MKTX stock pages for the full models.
Not investment advice.